Humberto Choi1, Vikram Puvenna2, Chanda Brennan2, Shamseldeen Mahmoud3, Xiao-Feng Wang4, Michael Phillips3, Damir Janigro2, Peter Mazzone1. 1. Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA ; 2. Cerebrovascular Research, Biomedical Engineering and Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA ; 3. Imaging Institute, Cleveland Clinic, Cleveland, OH 44195, USA. 4. Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH 44195, USA.
Abstract
BACKGROUND: S100B is an astrocytic protein that enters the blood stream when there is disruption of the blood-brain barrier (BBB). Over time, antibodies against S100B develop in the sera of patients who experience persistent or repeated BBB disruptions. We explored the use of serum S100B protein and S100B autoantibodies for the detection of brain metastasis in patients with lung cancer. METHODS: One hundred and twenty eight untreated patients with lung cancer who had brain imaging performed as part of their routine evaluation, participated. Serum S100B protein levels were measured by direct ELISA and S100B autoantibody levels by reverse ELISA. These levels in patients with brain metastases were compared alone and in combination to those without brain metastases. RESULTS: Eighteen (14%) patients had brain metastasis at the time of lung cancer diagnosis. An S100B cutoff of 0.058 ng/mL had a sensitivity of 89% and specificity of 43% for brain metastasis. When an autoantibody threshold of <2.00 absorbance units was used in conjunction with S100B, the sensitivity remained at 89%, and the specificity increased to 58%. The overall accuracy was 51% with S100B alone, improving to 62.5% when combined with autoantibodies. CONCLUSIONS: Serum S100B and S100B autoantibody levels may help to identify which lung cancer patients have brain metastases.
BACKGROUND:S100B is an astrocytic protein that enters the blood stream when there is disruption of the blood-brain barrier (BBB). Over time, antibodies against S100B develop in the sera of patients who experience persistent or repeated BBB disruptions. We explored the use of serum S100B protein and S100B autoantibodies for the detection of brain metastasis in patients with lung cancer. METHODS: One hundred and twenty eight untreated patients with lung cancer who had brain imaging performed as part of their routine evaluation, participated. Serum S100B protein levels were measured by direct ELISA and S100B autoantibody levels by reverse ELISA. These levels in patients with brain metastases were compared alone and in combination to those without brain metastases. RESULTS: Eighteen (14%) patients had brain metastasis at the time of lung cancer diagnosis. An S100B cutoff of 0.058 ng/mL had a sensitivity of 89% and specificity of 43% for brain metastasis. When an autoantibody threshold of <2.00 absorbance units was used in conjunction with S100B, the sensitivity remained at 89%, and the specificity increased to 58%. The overall accuracy was 51% with S100B alone, improving to 62.5% when combined with autoantibodies. CONCLUSIONS: Serum S100B and S100B autoantibody levels may help to identify which lung cancerpatients have brain metastases.
Authors: D Georgiadis; A Berger; E Kowatschev; C Lautenschläger; A Börner; A Lindner; W Schulte-Mattler; H R Zerkowski; S Zierz; T Deufel Journal: J Thorac Cardiovasc Surg Date: 2000-01 Impact factor: 5.209
Authors: Michael A Vogelbaum; Thomas Masaryk; Peter Mazzone; Tarek Mekhail; Vincent Fazio; Sally McCartney; Nicola Marchi; Andrew Kanner; Damir Janigro Journal: Cancer Date: 2005-08-15 Impact factor: 6.860
Authors: L O Wahlund; F Barkhof; F Fazekas; L Bronge; M Augustin; M Sjögren; A Wallin; H Ader; D Leys; L Pantoni; F Pasquier; T Erkinjuntti; P Scheltens Journal: Stroke Date: 2001-06 Impact factor: 7.914
Authors: Nicola Marchi; Peter Mazzone; Vincent Fazio; Tarek Mekhail; Thomas Masaryk; Damir Janigro Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Asad Ur Rehman; Parvez Khan; Shailendra Kumar Maurya; Jawed A Siddiqui; Juan A Santamaria-Barria; Surinder K Batra; Mohd Wasim Nasser Journal: Mol Cancer Date: 2022-05-10 Impact factor: 41.444